journal article·2002-01

The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides

Traian V Chirila, Piroska E Rakoczy, Kerryn L Garrett, Xia Lou, Ian J Constable

Biomaterials· Volume 23· Issue 2
Publisher page

Abstract

Developed over the past two decades, the antisense strategy has become a technology of recognised therapeutic potential, and many of the problems raised earlier in its application have been solved to varying extents. However, the adequate delivery of antisense oligodeoxynucleotides to individual cells remains an important and inordinately difficult challenge. Synthetic polymers appeared on this scene in the middle 1980s, and there is a surprisingly large variety used or proposed so far as agents for delivery of oligodeoxynucleotides. After discussing the principles of antisense strategy, certain aspects of the ingestion of macromolecules by cells, and the present situation of delivery procedures, this article analyses in detail the attempts to use synthetic polymers as carrier matrices and or cell membrane permeabilisation agents for delivery of antisense oligodeoxynucleotides. Structural aspects of various polymers, as well as the results, promises and limitations of their use are critically evaluated.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Prospects for human gene therapy10.1126/science.6093246 ↗
2. Progress toward human gene therapy10.1126/science.2660259 ↗
3. Altering the genome by homologous recombination10.1126/science.2660260 ↗
5. Gene therapy – promises, problems and prospects10.1038/38410 ↗
6. Overcoming the obstacles to gene therapy10.1038/scientificamerican0697-95 ↗
7. Therapeutic gene targeting10.1038/sj.gt.3300601 ↗
8. Facilitating oligonucleotide delivery10.1073/pnas.93.8.3161 ↗
9. Antisense technology10.3109/10611869808995877 ↗
10. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide10.1073/pnas.75.1.280 ↗
11. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide10.1073/pnas.75.1.285 ↗
12. Inhibition of thymidine kinase gene expression by anti-sense RNA10.1016/0092-8674(84)90050-3 ↗
13. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA10.1126/science.2990048 ↗
14. Antisense oligonucleotides10.1111/j.1470-8744.1997.tb00448.x ↗
15. Antisense pharmacodynamics10.1023/A:1011958726518 ↗
16. Non-viral gene therapy10.1016/0958-1669(94)90085-X ↗
17. Nonviral gene therapy10.1089/hum.1995.6.9-1129 ↗
18. Polymers in gene therapy
19. Nonviral strategies for gene therapy10.1038/scientificamerican0697-102 ↗
20. Antisense strategies in cell and developmental biology10.1242/jcs.97.3.399 ↗
21. Antisense oligonucleotides10.1021/cr00102a001 ↗
22. Antisense oligonucleotides
23. Therapeutic applications of oligonucleotides10.1146/annurev.pa.32.040192.001553 ↗
24. Artificial regulation of gene expression by complementary oligonucleotides – an overview
25. Antisense oligonucleotides10.1021/ar00057a002 ↗
27. Structural gene identification and mapping by DNA mRNA hybrid-arrested cell-free translation10.1073/pnas.74.10.4370 ↗
28. Antisense techniques
29. Cell delivery and mechanisms of action of antisense oligonucleotides10.1016/S0079-6603(08)60219-6 ↗
30. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents10.1007/BF02088837 ↗
31. Disrupting the flow of genetic information with antisense oligodeoxynucleotides
32. Development of targeted delivery systems for nucleic acid drugs10.3109/10611869709017892 ↗
33. Antisense oligonucleotides as therapeutic agents10.1006/phrs.1997.0227 ↗
34. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes10.1006/bmme.1997.2631 ↗
35. To cleave or not to cleave10.1089/ard.1995.5.227 ↗
36. Endocytosis
37. Inhibition of replication and expression of human T-cell lymphotrophic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA10.1073/pnas.83.12.4143 ↗
38. Characterization of oligonucleotide transport into living cells10.1073/pnas.86.10.3474 ↗
39. Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides
40. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells10.1089/ard.1993.3.235 ↗
41. Delivery of antisense oligonucleotides by poly(l-lysine) conjugation and liposome encapsulation
42. Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methylphosphonate oligonucleotides
43. Cellular internalization of oligodeoxynucleotides
44. In vivo pharmacokinetics of oligonucleotides following administration by different routes
45. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides10.1016/0168-3659(96)01361-2 ↗
46. Oligonucleotide biological activity10.1016/S0248-4900(97)82313-1 ↗
47. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes10.1073/pnas.91.8.3156 ↗
48. Oligonucleotide delivery
49. Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes10.1038/335519a0 ↗
50. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus10.1128/JVI.64.4.1716-1725.1990 ↗
51. Inhibition of human immunodeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for rev-response element stem-loop V10.1021/bi00194a002 ↗
52. Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion10.1128/JVI.69.6.3308-3314.1995 ↗
53. cAMP response element-binding protein in the amygdala is required for long-but not short-term conditioned taste aversion memory10.1523/JNEUROSCI.17-21-08443.1997 ↗
54. Electroporation of synthetic oligonucleotides10.1182/blood.V88.2.731.bloodjournal882731 ↗
55. Retrovirally transduced antisense sequences stably suppress P210 BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines10.1182/blood.V81.2.502.502 ↗
56. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia10.1073/pnas.90.18.8474 ↗
57. In vivo transfer efficiency of antisense oilgonucleotides into the myocardium using HVJ-liposome method10.1006/bbrc.1996.5762 ↗
58. HVJ (Sendai virus)-cationic liposomes10.1038/sj.gt.3300463 ↗
59. Liposomes as a drug delivery system for antisense oligonucleotides10.1089/ard.1992.2.165 ↗
60. Use of cationic lipids to enhance the biological activity of antisense oilgonucleotides10.3109/08982109309147445 ↗
61. Liposomes as a delivery system for antisense and ribozyme compounds
62. Intracellular delivery of oligonucleotides with cationic liposomes
63. The delivery of oilgonucleotides using pH sensitive liposomes
64. Liposomal delivery of oligodeoxynucleotides10.3109/10428199609067585 ↗
65. Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid10.1016/0168-3659(96)01362-4 ↗
66. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system10.1006/bbrc.1997.7191 ↗
67. In vivo delivery of phosphorothioate oligonucleotides into murine retina10.1001/archopht.116.3.342 ↗
68. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus10.1093/nar/26.8.2016 ↗
69. Intravitreal administration of antisense oligonucleotides10.1016/S1350-9462(99)00014-2 ↗
70. Limitations of cationic liposomes for antisense oligonucleotide delivery in vivo10.3109/08982109709035481 ↗
71. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells10.1093/nar/21.16.3857 ↗
72. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines10.1126/science.7684856 ↗
73. Gene inhibition using antisense oligodeoxynucleotides10.1038/372333a0 ↗
75. Combination between different proteins and between proteins and yeast nucleic acid10.1042/bj0400677 ↗
76. Studies on infection with Bacillus anthracis. IV. Preparation and characterization of an anthracidal substance from various animal tissues10.1093/infdis/80.1.41 ↗
77. Studies on infection with Bacillus anthracis. VII. A comparison of the antibacterial effects of calf thymus histone and a quaternary ammonium cationic detergent on B. anthracis10.1093/infdis/80.2.145 ↗
78. Agglutination of red cells by synthetic lysine polypeptides10.3181/00379727-76-18587 ↗
79. Inhibitory effect of synthetic lysine polypeptides on growth of influenza virus in embryonated eggs10.3181/00379727-76-18588 ↗
80. The inhibition of tobacco mosaic virus by synthetic lysine polypeptides10.1016/S0021-9258(18)56093-2 ↗
81. The combination of lysine polypeptides with tobacco mosaic virus10.1016/S0021-9258(19)52422-X ↗
82. The agglutination and growth inhibition of bacteria by lysine polypeptides10.1016/0003-9861(52)90257-9 ↗
83. The action of some water-soluble poly-α-amino acids on bacteria10.1042/bj0550671 ↗
84. Interaction of basic polyamino acids with the red blood cell. I. Combination of polylysine with single cells10.1016/0006-3002(55)90416-9 ↗
85. Interactions of basic polyelectrolytes with the red blood cell. II. Agglutination of red blood cells by polymeric bases10.1016/0006-3002(59)90505-0 ↗
86. An agar cell-suspension plaque assay for isolated viral RNA10.1016/0006-291X(66)90155-0 ↗
87. The effect of polycations on the interaction of viral RNA with mammalian cells10.1016/0042-6822(68)90300-0 ↗
88. Plaque assay for poliovirus and poliovirus specific RNAs
89. Influence of polycations on the interaction between poliovirus multistranded ribonucleic acid and HeLa cells10.1128/JVI.8.1.35-40.1971 ↗
90. Infection of tobacco mesophyll protoplats by tobacco mosaic virus10.1073/pnas.64.3.843 ↗
91. Effect of DEAE-dextran on production of interferon induced by synthetic double-stranded RNA in L cell cultures10.3181/00379727-128-33105 ↗
92. Cell interaction with a synthetic polynucleotide and interferon production in vitro10.1016/0042-6822(69)90097-X ↗
93. Interferon induction by single-stranded polynucleotides modified with polybases10.1099/0022-1317-24-2-385 ↗
94. Binding of basic proteins to DNA10.1016/S0022-2836(65)80178-4 ↗
95. Interaction of poly-l-lysine and nucleic acids10.1016/S0022-2836(66)80225-5 ↗
96. Template properties of DNA–polypeptide complexes10.1016/0022-2836(70)90196-8 ↗
97. The preferential interactions of polylysine and polyarginine with specific base sequences in DNA10.1073/pnas.56.4.1325 ↗
98. Model nucleoprotein complexes10.1016/0022-2836(67)90324-5 ↗
99. Helix–coil transition in nucleoprotein-chromatin structure10.1021/bi00733a016 ↗
100. Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture10.1126/science.150.3695.501 ↗